CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice

Alla Akkerman, Weiqing Huang, Xiaobo Wang, Meera Ramanujam, Lena Schiffer, Michael P. Madaio, Stephen M. Factor, Anne Davidson

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

NZW "x" BXSB F1 mice develop SLE that is associated with an anti-phospholipid syndrome characterized by anti-cardiolipin antibodies, thrombocytopenia and small coronary artery thrombosis. This syndrome is immune mediated and, dependent, on CD4+T cells. To determine whether disease in these mice can be treated with blockade of T cell costimulation we treated them with the CD28 antagonist CTLA4Ig at 9 or 12 weeks of age. CTLA4Ig completely prevented both SLE nephritis and myocardial infarcts if it was given at 9 weeks of age, before anti-cardiolipin antibodies could be detected in the serum and prevented both B cell expansion and activation and the development of peripheral monocytosis. If treatment was delayed until 12 weeks of age after cardiolipin antibodies had arisen but before the onset of clinical disease, CTLA4Ig had very little effect on disease progression. These findings indicate that CD4+T cell activation through CD28 is critical for disease initiation in this model but plays little role in disease progression or tissue damage. These findings have relevance to the treatment of anti-phospholipid syndrome in humans.

Original languageEnglish (US)
Pages (from-to)445-451
Number of pages7
JournalAutoimmunity
Volume37
Issue number6-7
DOIs
StatePublished - Sep 1 2004

Fingerprint

Cardiolipins
Antiphospholipid Syndrome
T-Lymphocytes
Disease Progression
Anti-Idiotypic Antibodies
Coronary Thrombosis
Nephritis
Thrombocytopenia
Coronary Vessels
B-Lymphocytes
Myocardial Infarction
Antibodies
Therapeutics
Serum

Keywords

  • Anti-phospholipid syndrome
  • CTLA4Ig
  • NZW/BXSB mice
  • SLE

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Akkerman, A., Huang, W., Wang, X., Ramanujam, M., Schiffer, L., Madaio, M. P., ... Davidson, A. (2004). CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity, 37(6-7), 445-451. https://doi.org/10.1080/08916930400008524

CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. / Akkerman, Alla; Huang, Weiqing; Wang, Xiaobo; Ramanujam, Meera; Schiffer, Lena; Madaio, Michael P.; Factor, Stephen M.; Davidson, Anne.

In: Autoimmunity, Vol. 37, No. 6-7, 01.09.2004, p. 445-451.

Research output: Contribution to journalArticle

Akkerman, A, Huang, W, Wang, X, Ramanujam, M, Schiffer, L, Madaio, MP, Factor, SM & Davidson, A 2004, 'CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice', Autoimmunity, vol. 37, no. 6-7, pp. 445-451. https://doi.org/10.1080/08916930400008524
Akkerman A, Huang W, Wang X, Ramanujam M, Schiffer L, Madaio MP et al. CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity. 2004 Sep 1;37(6-7):445-451. https://doi.org/10.1080/08916930400008524
Akkerman, Alla ; Huang, Weiqing ; Wang, Xiaobo ; Ramanujam, Meera ; Schiffer, Lena ; Madaio, Michael P. ; Factor, Stephen M. ; Davidson, Anne. / CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. In: Autoimmunity. 2004 ; Vol. 37, No. 6-7. pp. 445-451.
@article{0143c60bac7245fd835f380c0eab8758,
title = "CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice",
abstract = "NZW {"}x{"} BXSB F1 mice develop SLE that is associated with an anti-phospholipid syndrome characterized by anti-cardiolipin antibodies, thrombocytopenia and small coronary artery thrombosis. This syndrome is immune mediated and, dependent, on CD4+T cells. To determine whether disease in these mice can be treated with blockade of T cell costimulation we treated them with the CD28 antagonist CTLA4Ig at 9 or 12 weeks of age. CTLA4Ig completely prevented both SLE nephritis and myocardial infarcts if it was given at 9 weeks of age, before anti-cardiolipin antibodies could be detected in the serum and prevented both B cell expansion and activation and the development of peripheral monocytosis. If treatment was delayed until 12 weeks of age after cardiolipin antibodies had arisen but before the onset of clinical disease, CTLA4Ig had very little effect on disease progression. These findings indicate that CD4+T cell activation through CD28 is critical for disease initiation in this model but plays little role in disease progression or tissue damage. These findings have relevance to the treatment of anti-phospholipid syndrome in humans.",
keywords = "Anti-phospholipid syndrome, CTLA4Ig, NZW/BXSB mice, SLE",
author = "Alla Akkerman and Weiqing Huang and Xiaobo Wang and Meera Ramanujam and Lena Schiffer and Madaio, {Michael P.} and Factor, {Stephen M.} and Anne Davidson",
year = "2004",
month = "9",
day = "1",
doi = "10.1080/08916930400008524",
language = "English (US)",
volume = "37",
pages = "445--451",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "6-7",

}

TY - JOUR

T1 - CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice

AU - Akkerman, Alla

AU - Huang, Weiqing

AU - Wang, Xiaobo

AU - Ramanujam, Meera

AU - Schiffer, Lena

AU - Madaio, Michael P.

AU - Factor, Stephen M.

AU - Davidson, Anne

PY - 2004/9/1

Y1 - 2004/9/1

N2 - NZW "x" BXSB F1 mice develop SLE that is associated with an anti-phospholipid syndrome characterized by anti-cardiolipin antibodies, thrombocytopenia and small coronary artery thrombosis. This syndrome is immune mediated and, dependent, on CD4+T cells. To determine whether disease in these mice can be treated with blockade of T cell costimulation we treated them with the CD28 antagonist CTLA4Ig at 9 or 12 weeks of age. CTLA4Ig completely prevented both SLE nephritis and myocardial infarcts if it was given at 9 weeks of age, before anti-cardiolipin antibodies could be detected in the serum and prevented both B cell expansion and activation and the development of peripheral monocytosis. If treatment was delayed until 12 weeks of age after cardiolipin antibodies had arisen but before the onset of clinical disease, CTLA4Ig had very little effect on disease progression. These findings indicate that CD4+T cell activation through CD28 is critical for disease initiation in this model but plays little role in disease progression or tissue damage. These findings have relevance to the treatment of anti-phospholipid syndrome in humans.

AB - NZW "x" BXSB F1 mice develop SLE that is associated with an anti-phospholipid syndrome characterized by anti-cardiolipin antibodies, thrombocytopenia and small coronary artery thrombosis. This syndrome is immune mediated and, dependent, on CD4+T cells. To determine whether disease in these mice can be treated with blockade of T cell costimulation we treated them with the CD28 antagonist CTLA4Ig at 9 or 12 weeks of age. CTLA4Ig completely prevented both SLE nephritis and myocardial infarcts if it was given at 9 weeks of age, before anti-cardiolipin antibodies could be detected in the serum and prevented both B cell expansion and activation and the development of peripheral monocytosis. If treatment was delayed until 12 weeks of age after cardiolipin antibodies had arisen but before the onset of clinical disease, CTLA4Ig had very little effect on disease progression. These findings indicate that CD4+T cell activation through CD28 is critical for disease initiation in this model but plays little role in disease progression or tissue damage. These findings have relevance to the treatment of anti-phospholipid syndrome in humans.

KW - Anti-phospholipid syndrome

KW - CTLA4Ig

KW - NZW/BXSB mice

KW - SLE

UR - http://www.scopus.com/inward/record.url?scp=12344279919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344279919&partnerID=8YFLogxK

U2 - 10.1080/08916930400008524

DO - 10.1080/08916930400008524

M3 - Article

VL - 37

SP - 445

EP - 451

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 6-7

ER -